Published January 14, 2025
Danaher vs Thermo Fisher: Plasmid Manufacturing & Gene Therapy Positioning
inpractise.com/articles/danaher-vs-thermo-fisher-plasmid-manufacturing-and-gene-therapy-positioning
Executive Bio
Former VP of Sales, Aldevron
Interview Transcript
Disclaimer: This interview is for informational purposes only and should not be relied upon as a basis for investment decisions. In Practise is an independent publisher and all opinions expressed by guests are solely their own opinions and do not reflect the opinion of In Practise.
This is a snippet of the transcript.to get full access.
How difficult is it for new entrants to come in and manufacture plasmids?
It's amusing how many conversations we have with people who grow a bit of plasmid in a lab and don't understand the complexities involved. They often ask, "Why can't you just make it?" LB broth is inexpensive, so they suggest making a bigger batch. However, it becomes cumbersome when you start using 30-liter fermenters and above. You need a lot of expertise to lyse the cells and maintain DNA integrity, especially with AAV, which is prevalent in the market. The transgene, the main component sourced, is a large plasmid and doesn't behave well at large scales.
Free Sample of 50+ Interviews
Sign up to test our content quality with a free sample of 50+ interviews.
Or contact sales for full access
Related Content
© 2024 In Practise. All rights reserved. This material is for informational purposes only and should not be considered as investment advice.
